PHREESIA INC (PHR) Stock Fundamental Analysis
NYSE:PHR - New York Stock Exchange, Inc. - US71944F1066 - Common Stock - Currency: USD
PHR gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 37 industry peers in the Health Care Technology industry. While PHR seems to be doing ok healthwise, there are quite some concerns on its profitability. PHR is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
PHR had negative earnings in the past year.
In the past year PHR had a positive cash flow from operations.
PHR had negative earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: PHR reported negative operating cash flow in multiple years.
1.2 Ratios
PHR's Return On Assets of -15.07% is in line compared to the rest of the industry. PHR outperforms 56.76% of its industry peers.
The Return On Equity of PHR (-22.10%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.07% | ||
| ROE | -22.1% | ||
| ROIC | N/A |
ROA(3y)-33.2%
ROA(5y)-26.37%
ROE(3y)-45.91%
ROE(5y)-35.28%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PHR has a Gross Margin of 67.86%. This is in the better half of the industry: PHR outperforms 72.97% of its industry peers.
In the last couple of years the Gross Margin of PHR has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for PHR so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 67.86% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.16%
GM growth 5Y1.12%
2. Health
2.1 Basic Checks
PHR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PHR has more shares outstanding
The number of shares outstanding for PHR has been increased compared to 5 years ago.
The debt/assets ratio for PHR is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 4.81 indicates that PHR is not in any danger for bankruptcy at the moment.
PHR has a better Altman-Z score (4.81) than 81.08% of its industry peers.
The Debt to FCF ratio of PHR is 1.95, which is an excellent value as it means it would take PHR, only 1.95 years of fcf income to pay off all of its debts.
With a decent Debt to FCF ratio value of 1.95, PHR is doing good in the industry, outperforming 78.38% of the companies in the same industry.
PHR has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
PHR has a Debt to Equity ratio of 0.03. This is comparable to the rest of the industry: PHR outperforms 59.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | 1.95 | ||
| Altman-Z | 4.81 |
ROIC/WACCN/A
WACC10.56%
2.3 Liquidity
PHR has a Current Ratio of 1.78. This is a normal value and indicates that PHR is financially healthy and should not expect problems in meeting its short term obligations.
PHR has a Current ratio (1.78) which is in line with its industry peers.
PHR has a Quick Ratio of 1.78. This is a normal value and indicates that PHR is financially healthy and should not expect problems in meeting its short term obligations.
PHR has a Quick ratio (1.78) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.78 | ||
| Quick Ratio | 1.78 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 13.56% over the past year.
PHR shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 17.82%.
The Revenue has been growing by 27.46% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)13.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.62%
Revenue 1Y (TTM)17.82%
Revenue growth 3Y25.34%
Revenue growth 5Y27.46%
Sales Q2Q%15.45%
3.2 Future
The Earnings Per Share is expected to grow by 55.07% on average over the next years. This is a very strong growth
Based on estimates for the next years, PHR will show a quite strong growth in Revenue. The Revenue will grow by 11.64% on average per year.
EPS Next Y79.86%
EPS Next 2Y51%
EPS Next 3Y55.07%
EPS Next 5YN/A
Revenue Next Year13.62%
Revenue Next 2Y12.75%
Revenue Next 3Y12.62%
Revenue Next 5Y11.64%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for PHR. In the last year negative earnings were reported.
Also next year PHR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
PHR's Price/Free Cash Flow ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 169.89 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PHR's earnings are expected to grow with 55.07% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y51%
EPS Next 3Y55.07%
5. Dividend
5.1 Amount
PHR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
23.97
+0.08 (+0.33%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners99.8%
Inst Owner Change0%
Ins Owners5.25%
Ins Owner Change-3.78%
Market Cap1.41B
Analysts85.26
Price Target33.32 (39.01%)
Short Float %3.74%
Short Ratio4.8
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.88%
Min EPS beat(2)8.94%
Max EPS beat(2)38.81%
EPS beat(4)4
Avg EPS beat(4)22.42%
Min EPS beat(4)8.94%
Max EPS beat(4)38.81%
EPS beat(8)8
Avg EPS beat(8)22.4%
EPS beat(12)12
Avg EPS beat(12)21.82%
EPS beat(16)14
Avg EPS beat(16)4.17%
Revenue beat(2)0
Avg Revenue beat(2)-0.43%
Min Revenue beat(2)-0.56%
Max Revenue beat(2)-0.3%
Revenue beat(4)0
Avg Revenue beat(4)-0.55%
Min Revenue beat(4)-0.75%
Max Revenue beat(4)-0.3%
Revenue beat(8)3
Avg Revenue beat(8)0.19%
Revenue beat(12)7
Avg Revenue beat(12)0.67%
Revenue beat(16)11
Avg Revenue beat(16)2.64%
PT rev (1m)2.31%
PT rev (3m)8.12%
EPS NQ rev (1m)-1.97%
EPS NQ rev (3m)41.37%
EPS NY rev (1m)29.87%
EPS NY rev (3m)54.11%
Revenue NQ rev (1m)-0.27%
Revenue NQ rev (3m)-1.26%
Revenue NY rev (1m)-0.11%
Revenue NY rev (3m)-0.11%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 3.36 | ||
| P/FCF | 169.89 | ||
| P/OCF | 43.5 | ||
| P/B | 5.32 | ||
| P/tB | 13.04 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.02
EYN/A
EPS(NY)-0.21
Fwd EYN/A
FCF(TTM)0.14
FCFY0.59%
OCF(TTM)0.55
OCFY2.3%
SpS7.14
BVpS4.51
TBVpS1.84
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.07% | ||
| ROE | -22.1% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 67.86% | ||
| FCFM | 1.98% |
ROA(3y)-33.2%
ROA(5y)-26.37%
ROE(3y)-45.91%
ROE(5y)-35.28%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.16%
GM growth 5Y1.12%
F-Score6
Asset Turnover1.08
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | 1.95 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 86.38% | ||
| Cap/Sales | 5.74% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.78 | ||
| Quick Ratio | 1.78 | ||
| Altman-Z | 4.81 |
F-Score6
WACC10.56%
ROIC/WACCN/A
Cap/Depr(3y)91.68%
Cap/Depr(5y)107.3%
Cap/Sales(3y)7.37%
Cap/Sales(5y)9.81%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.62%
EPS Next Y79.86%
EPS Next 2Y51%
EPS Next 3Y55.07%
EPS Next 5YN/A
Revenue 1Y (TTM)17.82%
Revenue growth 3Y25.34%
Revenue growth 5Y27.46%
Sales Q2Q%15.45%
Revenue Next Year13.62%
Revenue Next 2Y12.75%
Revenue Next 3Y12.62%
Revenue Next 5Y11.64%
EBIT growth 1Y57.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year236.17%
EBIT Next 3Y65.19%
EBIT Next 5Y35.77%
FCF growth 1Y114.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y200.01%
OCF growth 3YN/A
OCF growth 5Y108.09%